Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 3/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2929686 | 0.84 | DRD3 (0.48) | CYP19A1HTR1ASIGMAR1 | |
| SCHEMBL9139949 | 0.84 | HTR1A (0.53) | CYP19A1HTR1APLAUSIGMAR1MTNR1A | |
| SCHEMBL2070610 | 0.83 | CYP19A1 (0.54) | CYP19A1HTR1APLAUSIGMAR1MAOA | |
| SCHEMBL10616682 | 0.81 | GBA1 (0.52) | CYP19A1HTR1APLAUSIGMAR1MTNR1A | |
| SCHEMBL28334724 | 0.81 | CYP19A1 (0.38) | CYP19A1HTR1ASIGMAR1ADRA1DADRA1A | |
| SCHEMBL28012406 | 0.80 | CA1 (0.53) | CYP19A1HTR1APLAUSIGMAR1OPRM1 | |
| SCHEMBL6734633 | 0.80 | CYP19A1 (0.47) | CYP19A1HTR1APLAUSIGMAR1MTNR1A | |
| SCHEMBL1689673 | 0.80 | CYP19A1 (0.47) | CYP19A1HTR1APLAUSIGMAR1MTNR1A | |
| SCHEMBL24258319 | 0.80 | ADRA1D (0.57) | CYP19A1HTR1ASIGMAR1MTNR1AMTNR1B | |
| SCHEMBL11076774 | 0.80 | GBA1 (0.55) | CYP19A1HTR1APLAUSIGMAR1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-63002942-A | — | — | None | — | — | JP | disclosed |
| EP-3436446-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-06-07 | — | — | EP | disclosed |
| US-9394260-B2 | Pyrimidinone carboxamide inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150361052-A1 | PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-17 | — | — | US | disclosed |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8114997-B2 | N4-acylcytosine nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-RE42015-E1 | N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| WO-2008136642-A1 | NAPHTHOQUINONE-BASED PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | MAZENCE INC. (KR) | 2008-11-13 | — | — | WO | disclosed |
| EP-1379602-B1 | PROCESS FOR THE MANUFACTURE OF TEMPERATURE-SENSITIVE POLYMERS | SOLUTIA INC (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20040162408-A1 | PROCESS FOR THE MANUFACTURE OF TEMPERATURE-SENSITIVE POLYMERS | SOLUTIA INC. (US) | 2004-08-19 | — | — | US | disclosed |
| EP-1379602-A1 | PROCESS FOR THE MANUFACTURE OF TEMPERATURE-SENSITIVE POLYMERS | Solutia Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | GILEAD PHARMASSET LLC | 2003-09-18 | — | — | US | disclosed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003063771-A2 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET LTD. (BB) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003051306-A2 | N4-ACYLCYTOSINE-1,3-DIOXOLANE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| US-20020165421-A1 | Process for the manufacture of temperature-sensitive polymers | SOLUTIA INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2002083812-A1 | PROCESS FOR THE MANUFACTURE OF TEMPERATURE-SENSITIVE POLYMERS | SOLUTIA INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| JP-S632942-A | PRODUCTION OF ALKYL, FORMYLTETRALIN | SUMIKIN CHEM CO LTD | 1988-01-07 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, NT5C3B, PNP | CYP19A1 3276/4885HTR1A 3737/4885PLAU 2518/4885 |
| US-20150361052-A1 | PYRIMIDINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LPL, PNLIP | CYP19A1 579/4885HTR1A 1946/4885PLAU 250/4885 |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | ENTPD5, CDA, ADA | CYP19A1 911/4885HTR1A 3521/4885PLAU 3379/4885 |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | CYP19A1 1041/4885HTR1A 2750/4885PLAU 2755/4885 |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, DUT, NT5C3B | CYP19A1 3097/4885HTR1A 3868/4885PLAU 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.